Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986166 or Branebrutinib in Moderate to Severe Atopic Dermatitis
NCT05014438Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of udifitimod, branebrutinib in atopic dermatitis (AD), sponsored by Bristol Myers Squibb. Started Aug 2021; status: completed.
02
Drugs
udifitimodbranebrutinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05014438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05014438.